Capricor Therapeutics (NASDAQ:CAPR) has been granted a Type B End-of-Phase 2 meeting with the FDA to discuss the prespecified interim analysis of its HOPE 2 trial that evaluated CAP-1002 in steroid-treated boys and young men with Duchenne muscular dystrophy (DMD).
The analysis was consistent with the positive results seen the HOPE-Duchenne study.
Shares up 2% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.